These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 7926060)
1. IgA/VCA as a follow-up marker in the monitoring of nasopharyngeal carcinoma. Sam CK; Abu-Samah AJ; Prasad U Eur J Surg Oncol; 1994 Oct; 20(5):561-4. PubMed ID: 7926060 [TBL] [Abstract][Full Text] [Related]
2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282 [TBL] [Abstract][Full Text] [Related]
3. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486 [TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Tsang RK; Vlantis AC; Ho RW; Tam JS; To KF; van Hasselt CA Head Neck; 2004 Jul; 26(7):598-602. PubMed ID: 15229902 [TBL] [Abstract][Full Text] [Related]
5. [Significance of detection of serum sialic acid and Epstein-Barr virus VCA-IgA in diagnosis and monitoring radiotherapy effectiveness in nasopharyngeal carcinoma patients]. Jiang LN; Dai LC; He JF; Chen YW; Ma ZH Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):30-2. PubMed ID: 16816858 [TBL] [Abstract][Full Text] [Related]
6. [Immunoglobulin A serum antibodies against the capsid antigen of Epstein-Barr virus in the differential diagnosis and follow-up of nasopharyngeal cancer]. Pavelka R; Popow-Kraupp T; Radaszkiewicz T Wien Klin Wochenschr; 1985 Jul; 97(14):588-95. PubMed ID: 2996246 [TBL] [Abstract][Full Text] [Related]
7. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma. Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805 [TBL] [Abstract][Full Text] [Related]
8. Enhancing the efficiency of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma. Zhang C; Zong Y; Huang B; Sun Y; Ye Y; Feng K; Li J; Zhang F Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):356-9. PubMed ID: 12408763 [TBL] [Abstract][Full Text] [Related]
9. Epstein Barr virus (EBV) antibodies in the diagnosis of NPC--comparison between IFA and two commercial ELISA kits. Chan SH; Soo MY; Gan YY; Fones-Tan A; Sim PS; Kaur A; Chew CT Singapore Med J; 1998 Jun; 39(6):263-5. PubMed ID: 9803815 [TBL] [Abstract][Full Text] [Related]
10. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma. Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Liu MT; Yeh CY Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898 [TBL] [Abstract][Full Text] [Related]
12. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma]. Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192 [TBL] [Abstract][Full Text] [Related]
13. [Expression of P53 and PCNA in nasopharyngeal carcinoma and their relation with clinical stage, VCA/IgA, EA/IgA, radiation sensibility, and pognosis]. Mo HY; Zhang CQ; Feng KT; Zhang F; Hong MH; Sun ZY Ai Zheng; 2004 Nov; 23(11 Suppl):1551-4. PubMed ID: 15566678 [TBL] [Abstract][Full Text] [Related]
15. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong. Lo S; Ho WK; Wei WI Arch Otolaryngol Head Neck Surg; 2004 Jun; 130(6):770-2. PubMed ID: 15210561 [TBL] [Abstract][Full Text] [Related]
16. Histological types of nasopharyngeal carcinoma as compared to EBV serology. Krueger GR; Kottaridis SD; Wolf H; Ablashi DV; Sesterhenn K; Bertram G Anticancer Res; 1981; 1(4):187-94. PubMed ID: 6285799 [TBL] [Abstract][Full Text] [Related]
17. [Immunohistochemical and cytochemical analysis of lymphocytes and plasma cells in nasopharyngeal carcinoma]. Huang PS; Shen YY Zhonghua Zhong Liu Za Zhi; 1986 May; 8(3):187-9. PubMed ID: 3017661 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842 [TBL] [Abstract][Full Text] [Related]
19. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx]. Mazeron MC Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]